

July 20, 2023  
 SymBio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director  
 President and Chief Executive Officer  
 (Securities Code: 4582)

**Notice of Personnel Changes at SymBio Pharma USA, Inc.**

TOKYO, July 20, 2023 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, hereinafter “SymBio”) today announced the appointment of Stephane Berthier as CEO and President of SymBio Pharma USA, Inc. (established in May 2016; wholly owned US subsidiary; representative: Fuminori Yoshida; hereinafter “SPU”), effective August 1, 2023, and at the same time, as a Corporate Officer of SymBio. With this appointment, SPU will further develop its full-scale operations with a mission to drive the development of the intravenous formulation of brincidofovir (“IV BCV”) toward commercialization in Europe, the U.S., and Japan.

Statement from Dr. Stephane Berthier: “This is an exciting time to join SPU as SymBio enters an exciting phase of global development to deliver innovative medicines in underserved therapeutic areas across the globe. I look forward to building a strong global organization from both a culture and capabilities standpoint to support SymBio's patient-oriented approach.”

Statement from Fuminori Yoshida, President and CEO of SymBio: “We are very pleased to welcome Dr. Stephane Berthier, with his outstanding knowledge and experience, to our management team. We will further accelerate SymBio's global business development and our transformation into a global specialty pharmaceutical company with him.”

Effective August 1, Fuminori Yoshida, President and CEO, will also serve as Chairman of the Board of SPU, and Takaaki Fukushima, Managing Corporate Officer and CFO, will also serve as Director of SPU. Dr. Carolyn Yanavich will step down as President and COO of SPU.

**SymBio Pharma USA, Inc. (summary)**

Name	SymBio Pharma USA, Inc. (SPU)
Address	Durham, North Carolina, USA
Representative	Fuminori Yoshida
Establishment Date	May 10, 2016
Shareholders	A 100% subsidiary of SymBio Pharmaceuticals Limited
Business Activities	Research and development of pharmaceutical products

**1. Appointment of Corporate Officer of Symbio**

Name	Title
Stephane Berthier	Corporate Officer (CEO and President of SPU)

**2. Date of appointment: August 1, 2023**

**3. Profile of the newly appointed Corporate Officer**

1999	Laboratory Head Pharmacokinetics & Bioanalytics, Novartis (Switzerland)
2003	Director, Global Program Management, Novartis Oncology (Switzerland)
2006	Sales Manager, US Sales, Novartis Oncology (USA)
2011	Director, Global Commercial, Novartis Oncology (USA)
2013	US Brand Lead, Hematology, Novartis Oncology (USA)
2016	Global Business Head - Lymphoma & Leukemia, Janssen Pharmaceuticals (USA)
2019	Vice President, US Sales, Marketing & Operations, MorphoSys (USA)
2021	US General Manager, Atara Biotherapeutics (USA)
1997	PharmD (Doctor of Pharmacy), University René Descartes, France
2006	MBA, Lancaster University Management School, United Kingdom

**About the anti-viral drug Brincidofovir**

Brincidofovir (BCV) has a new mechanism of action as a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved and marketed in the United States and the European Union, but unapproved in Japan. BCV is expected to be an effective treatment against a wide spectrum of dsDNA virus infections (cytomegalovirus, adenovirus, Epstein-Barr virus, herpes virus, BK virus, papillomavirus and smallpox virus including monkeypox, etc.), with superior features such as high activity antiviral effect in comparison with CDV and other antiviral drugs.

Due to the breakthrough nature of the BCV molecule, in which a specific length of lipid chain is attached to the CDV, BCV is converted into a molecule that acts directly within the cell, thereby dramatically increasing the efficiency of cellular uptake and showing a high antiviral activity.

In September 2019, Symbio entered into a license agreement with Chimerix for the exclusive worldwide rights to develop, market, and manufacture BCV for all diseases except orthopoxviruses (such as smallpox and monkeypox).

The tablets and oral suspension (oral formulation) were approved on June 4, 2021, for the treatment of smallpox in adults and pediatric patients, including neonates.

In addition to its high antiviral activity, BCV is also expected to have anti-tumor effects. We are currently conducting collaborative studies with the National Cancer Center of Singapore, the University of California, San Francisco, and other institutions to confirm its anti-cancer activity and to identify synergistic effects when combined with its antiviral activity.

Clinical trials and major R&D collaborations with prominent research institutions are underway as follows:

- Initiated a Phase II clinical trial in patients with adenovirus infection after hematopoietic stem cell transplantation (March 2021) and received Fast Track designation from the FDA (April 2021). Proof of Concept (POC) of antiviral efficacy established based on data up to cohort 3 (May 2023).
- Initiated Phase II clinical trial in patients with BK virus infection after renal transplantation (May 2022).
- Initiated a non-clinical trial at the University of California, San Francisco Neurosurgery Brain Tumor Center to evaluate the anti-tumor effect of BCV on refractory brain tumors (September 2021).
- With regard to multiple sclerosis, an intractable disease that has recently been proven to be associated with the EB virus, Symbio has entered into an Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS), affiliated with the National Institutes of Health (NIH), to examine BCV's efficacy against the EB virus in the treatment of multiple sclerosis, and to obtain information needed to conduct future clinical trials (March 2023).
- CRADA with the National Institute of Allergy and Infectious Diseases (NIAID), affiliated with the NIH, to evaluate the efficacy of BCV for EB virus-associated lymphoproliferative diseases (April 2023).
- Research on the involvement of infection by reactivation of latent viruses in various neurological severity diseases of the brain, including Alzheimer's disease, has been ongoing for the past several years, and a simple three-dimensional mimicry of human neural stem cell cultures and brain tissue established by Tufts University in the United States, the A Sponsored Research Agreement was signed (December 2022) to examine the effect of BCV on HSV infection using a herpes simplex virus (HSV) infection/reactivation model established by Tufts University in the U.S., which uses human neural stem cells cultured to mimic brain tissue in three dimensions.

#### **About Symbio Pharmaceuticals Limited.**

Symbio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., called Symbio Pharma USA, Inc. (Headquarters: Durham, North Carolina, representative: Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.

#### **[Contact]**

Investor Relations, Administrative Division

Tel: +81(0)3 5472 1125